Moderna Stock News

''Much Brighter Than Before'': COVID-19 Cases Plunge Across US Authored by Zachary Stieber via The Epoch Times (emphasis ours), COVID-19 case counts have dropped across the United States in recent days, stoking optimism that the Omicron-fueled wave is subsiding. People stop outside a COVID-19 testing site in New York City on Jan. 10, 2022. (Scott Heins/Getty Images) Thirty-four states have recorded a decrease in cases in recent days, not including states that reported a single-day drop, according to an Epoch Times analysis. That includes some of the states that saw huge Omicron-fueled increases, including New York, California, and Florida. Omicron is one of the newest variants of Covid19. [ ZH ]: Other states that have seen fewer cases recently include Alabama, Delaware, Georgia, Louisiana, Nevada, North Dakota, Oregon, and Pennsylvania. States in every region of the country have reported fewer cases, and a smaller number have also seen a lower number of people being admitted to hospitals with or for COVID-19.

Moderna (MRNA) shares are on track to record its worst monthly performance since its public debut in 2018

Several factors are dragging down these vaccine stocks.

South African Scientists Confirm Boosters Offer Little Protection From Omicron On Monday, a team of Israeli scientists publicized research showing that even a second booster dose of the Moderna or Pfizer mRNA vaccines doesn''t bestow complete immunity from the omicron variant. Now, just days later, their conclusion appears to have been corroborated by a team of South African researchers from the University of Cape Town and Stellenbosch University who observed seven individuals who had been infected with the omicron variant despite having been "boosted". The patients represented the first known cases of breakthrough infection by omicron, the researchers told the Lancet , the British medical journal where their findings were published. Keep in mind, the South African team used a very different approach. First of all, the patients they examined had only received a single booster dose (unlike with the Israeli study, which focused on patients who had received two doses). As for the study''s subjects, all of them were white, and four were participating in medical training at Cape Town hospitals.

NEW YORK , Jan. 19, 2022 /PRNewswire/ -- The number of people infected by the Omicron variant of COVID-19 has broken records since the new year had started. As a result of the new wave, testing kits are in short supply. According to Anthony S. Fauci , Chief Medical Adviser to President Biden, it is going to be very important "that we get a greater capability of testing, particularly when the demand for testing is so high, with the combination of the Omicron variant itself, as well as the holiday season, where people want to get that extra level of assuredness that they''re protected, even if you are vaccinated and boosted." This week, the government responded by launching a website where Americans can request a free, at-home COVID-19 test. Todos Medical Ltd. (OTC: TOMDF ), Moderna, Inc. (NASDAQ: MRNA ), Pfizer Inc. (NYSE: PFE ), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Vaxart, Inc. (NASDAQ: VXRT ) In the meantime, in New York , which is once again the epicenter of the pandemic in the U.S., it was announced that city officials are negotiating a temporary return to remote learning for tens of thousands of students who aren''t showing up for class. "The real analysis that shows we were on the right path.

These are the stocks posting the largest moves in midday trading.

Shares of vaccine makers, including Moderna Inc Full story available on Benzinga.com

Combined vaccine should be ready in time for winter infectious season in 2023, says drug firm’s chief executive

When it comes to Covid-19 vaccines, Pfizer (PFE) and Moderna (MRNA) get all the headlines. To an extent, that makes sense. After all, both Pfizers Comirnaty

Further, he said that Modernas omicron-specific booster shot could enter into human trials within weeks

NEW YORK , Jan. 14, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MGM, GE, CCL, T, and MRNA. Full story available on Benzinga.com

The vaccine mandate was aimed at private companies with more than 100 employees. The ruling upheld a mandate for healthcare workers.

Moderna co-founder tells Bloomberg News that 2022 may be the year the pandemic enters the endemic phase.

Leading COVID-19 vaccine makers Pfizer (PFE)/BioNTech (BNTX), Moderna (MRNA), and Novavax (NVAX) are trading lower in the pre-market amid concerns that their efforts to